Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-Term High-Dose vs Standard-Dose Vonoprazan Dual Therapy for H. Pylori Eradication
NCT07352098Not yet recruiting
- Sponsor
- Yueyue Li
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of vonoprazan in Helicobacter pylori infection (2 arms), sponsored by Yueyue Li. Primary endpoint: Helicobacter pylori eradication rate. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT07352098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07352098.